Martina Porter, MD, a Dermatologist, Beth Israel Deaconess Medical Center in Boston, MA, takes a deep dive into new four-year data on continuous treatment with secukinumab (Cosentyx, Novartis) in patients with hidradenitis suppurativa (HS) that was presented at the 10th annual Symposium on Hidradenitis Suppurativa Advances (SHSA) in Nashville, TN. “It’s very encouraging to know that out to four years, patients continue to maintain and even potentially improve their response over time,” she says. Dr. Porter also discusses the changing treatment landscape for HS. “We have many more treatment options now than we did seven or eight years ago when I started treating HS,” she says. “The enthusiasm and the energy around HS is just totally unmatched for any other disease state right now.” Dr. Porter also reveals the most famous person ever to have HS.
